Use Of Liquid Biopsy Assay Able To Identify Patients With Metastatic NSCLC Who Had Molecular Response To Pembrolizumab Based Immunotherapy, Study Shows

Cancer Network (4/7, Sternberg) reports, “Use of the Guardant360 liquid biopsy assay was able to identify patients with metastatic non–small cell lung cancer (NSCLC) who had a molecular response to pembrolizumab (Keytruda) based immunotherapy, which was l...